CMO Patel Naimish buys inaugural 1,508 shares of CRSP at $32.96 amid company's -90.0% annual revenue decline and $-106.4M net loss.
Patel Naimish, Chief Medical Officer, purchased 1,508 shares at $32.96 on 2025-04-03, establishing an initial position in CRSP. This is notable given the company's severe financial deterioration: annual revenue growth stands at -90.0% with a latest-quarter revenue of $889.0K, and the company posted a full-year net income of $-106.4M. The buy occurs when the stock trades 29.3% below its 52-week high of $76.78, and the 90-day decline of -13.3% suggests recent downward momentum. As a first-time buyer with no prior holdings, this represents a new commitment to company stock at a significantly depressed valuation relative to recent price history, though the company's profitability crisis remains unresolved.